[24] Douxfils J, Tamigniau A, Chatelain B, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban[J]. Thromb Haemost, 2013,110(4):723-731. DOI: 10.1160/TH13-04-0274.
[25] Francart SJ, Hawes EM, Deal AM, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels[J]. Thromb Haemost, 2014,111(6):1133-1140. DOI: 10.1160/TH13-10-0871.
[26] Gouin-Thibault I, Flaujac C, Delavenne X, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study[J]. Thromb Haemost, 2014,111(2):240-248. DOI: 10.1160/TH13-06-0470.
[27] Mayer K, Schulz S, Bernlochner I, et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry[J]. Thromb Haemost, 2014,112(2):342-351. DOI: 10.1160/TH13-10-0874.
[28] Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation[J]. JAMA, 2010,303(8):754-762. DOI: 10.1001/jama.2010.181.
[29] Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI[J]. JAMA, 2011,306(11):1215-1223. DOI: 10.1001/jama.2011.1332.
[30] Lee DH, Kim MH, Guo LZ, et al. Lower loading dose of prasugrel compared with conventional loading doses of clopidogrel and prasugrel in korean patients undergoing elective coronary angiography: a randomized controlled study evaluating pharmacodynamic efficacy. Korean Circ J，2014，44(6):386-393.
[31] Vivas D, Martín A, Bernardo E, et al. Impact of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Prasugrel-Inhibited Platelets: Results of a Prospective, Randomized, Crossover Study (the ECCLIPSE Trial). Circ Cardiovasc Interv，2015，8(5). pii: e002281.